Pfizer and Taisho Reach Deal for Schizophrenia Candidate
This article was originally published in PharmAsia News
Executive Summary
Pfizer finalized an agreement with Taisho Pharmaceutical to acquire development and commercialization rights outside Japan for a metabotropic glutamate receptor (mGluR) agonist, which brings the number of schizophrenia candidates in Pfizer's pipeline to six
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)